Immune Checkpoint Inhibitors Market to Reach $189.3 Billion, Globally by 2032 at 16.8% CAGR: Allied Market Research
January 25, 2024 07:36 ET
|
Allied Analytics LLP
Wilmington, New Castle, Delaware, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Immune Checkpoint Inhibitors Market By Type (CTLA-4 Inhibitor, PD-1...
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
January 11, 2023 07:10 ET
|
Syneos Health, Inc.
MORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with...
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
November 07, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash...
BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress
December 15, 2018 02:30 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
December 03, 2018 14:15 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...